JP2024517738A5 - - Google Patents
Info
- Publication number
- JP2024517738A5 JP2024517738A5 JP2023566493A JP2023566493A JP2024517738A5 JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5 JP 2023566493 A JP2023566493 A JP 2023566493A JP 2023566493 A JP2023566493 A JP 2023566493A JP 2024517738 A5 JP2024517738 A5 JP 2024517738A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- minutes
- dmt
- approximately
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163179679P | 2021-04-26 | 2021-04-26 | |
| US63/179,679 | 2021-04-26 | ||
| PCT/US2022/026396 WO2022232179A1 (en) | 2021-04-26 | 2022-04-26 | Novel n,n-dimethyltryptamine compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517738A JP2024517738A (ja) | 2024-04-23 |
| JP2024517738A5 true JP2024517738A5 (https=) | 2025-05-07 |
Family
ID=83694712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566493A Pending JP2024517738A (ja) | 2021-04-26 | 2022-04-26 | 新規のｎ，ｎ－ジメチルトリプタミン組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11602521B2 (https=) |
| EP (1) | EP4329879A4 (https=) |
| JP (1) | JP2024517738A (https=) |
| KR (1) | KR20240000516A (https=) |
| CN (1) | CN117320711A (https=) |
| AU (1) | AU2022267240A1 (https=) |
| BR (1) | BR112023022195A2 (https=) |
| CA (1) | CA3216889A1 (https=) |
| CL (1) | CL2023003191A1 (https=) |
| IL (1) | IL308074A (https=) |
| MX (1) | MX2023012651A (https=) |
| WO (1) | WO2022232179A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| CA3218110A1 (en) * | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| AU2022287974A1 (en) | 2021-06-09 | 2024-01-04 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023186837A1 (en) * | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Treatment of postnatal depression |
| CA3267555A1 (en) * | 2022-10-26 | 2024-05-02 | Atai Therapeutics, Inc. | Compositions of N-N-dimethyltryptamine (DMT) analogues and DMT, their manufacturing processes and their methods of use |
| DK202330319A1 (en) * | 2023-11-07 | 2025-05-27 | Fertin Pharma As | An adhesive oral disc for sustained release of cannabinoids |
| CN121194779A (zh) | 2023-03-31 | 2025-12-23 | 赛本英国有限公司 | 包含单胺抗抑郁剂和短效致幻剂的组合 |
| WO2025054397A1 (en) * | 2023-09-08 | 2025-03-13 | Atai Therapeutics, Inc. | Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof |
| WO2025076151A1 (en) * | 2023-10-02 | 2025-04-10 | Atai Therapeutics, Inc. | N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220079881A1 (en) | 2016-03-03 | 2022-03-17 | Ctt Pharma Inc. | Orally Administrable Composition |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| HUE069534T2 (hu) * | 2019-02-22 | 2025-03-28 | Gh Res Ireland Limited | 5-Metoxi-N,N-dimetiltriptamint (5-MeO-DMT) tartalmazó készítmény mentális rendellenességek kezelésében történõ alkalmazásra |
| FI4349407T3 (fi) | 2019-02-22 | 2025-06-02 | Gh Res Ireland Limited | 5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| US20220304980A1 (en) | 2019-07-04 | 2022-09-29 | SW Holdings, Inc | Metered dosing compositions and methods of use of psychedelic compounds |
| US20210015738A1 (en) * | 2019-07-17 | 2021-01-21 | Concept Matrix Solutions | Oral dissolvable film containing psychedelic compound |
| WO2021138564A1 (en) * | 2019-12-31 | 2021-07-08 | Cure Pharmaceutical Holding Corp. | Oral dissolvable film and method of manufacturing and using the same |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| EP4167992A1 (en) * | 2020-06-22 | 2023-04-26 | University of Zürich | Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy |
| EP4192451A4 (en) * | 2020-08-05 | 2024-08-14 | Universitätsspital Basel | METHOD OF ADMINISTERING INTRAVENOUS DMT FOR DMT-ASSISTED PSYCHOTHERAPY |
| AU2021343525A1 (en) | 2020-09-20 | 2023-05-18 | Tactogen Inc | Advantageous tryptamine compositions for mental disorders or enhancement |
-
2022
- 2022-04-26 JP JP2023566493A patent/JP2024517738A/ja active Pending
- 2022-04-26 KR KR1020237038175A patent/KR20240000516A/ko active Pending
- 2022-04-26 WO PCT/US2022/026396 patent/WO2022232179A1/en not_active Ceased
- 2022-04-26 EP EP22796577.9A patent/EP4329879A4/en active Pending
- 2022-04-26 MX MX2023012651A patent/MX2023012651A/es unknown
- 2022-04-26 IL IL308074A patent/IL308074A/en unknown
- 2022-04-26 US US17/730,013 patent/US11602521B2/en active Active
- 2022-04-26 CN CN202280031363.4A patent/CN117320711A/zh active Pending
- 2022-04-26 BR BR112023022195A patent/BR112023022195A2/pt unknown
- 2022-04-26 CA CA3216889A patent/CA3216889A1/en active Pending
- 2022-04-26 AU AU2022267240A patent/AU2022267240A1/en active Pending
-
2023
- 2023-10-25 CL CL2023003191A patent/CL2023003191A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517738A5 (https=) | ||
| JP2025142338A5 (https=) | ||
| CZ20013344A3 (cs) | Farmaceutický prostředek vhodný pro léčení erektilní dysfunkce | |
| JP2004534057A5 (https=) | ||
| JP6209495B2 (ja) | 上部消化管治療用医薬製剤 | |
| TW200815048A (en) | Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies | |
| JP2013501718A5 (https=) | ||
| JP2023076465A5 (https=) | ||
| US20210308040A1 (en) | Ketamine oral transmucosal delivery system | |
| JP2010504312A (ja) | 活性成分の経粘膜投与のためのガレノス的方式 | |
| JP4597273B2 (ja) | 経口組成物 | |
| CN101505724A (zh) | 阿利吉仑的盖伦制剂 | |
| ES2324769T3 (es) | Comprimido que comprende cetrizina y pseudoefedrina. | |
| JP2023506545A (ja) | アゴメラチンを含有する経粘膜治療システム | |
| JP2020524162A (ja) | 唾液中でメラトニンを可溶性にする酸性化剤を有する経口溶解メラトニン製剤 | |
| Sheoran | Buccal drug delivery system: A review | |
| CN101460144A (zh) | AchE-NMDA组合物干胶片 | |
| US20220401389A1 (en) | Transmucosal therapeutic system containing agomelatine | |
| ES2459203T3 (es) | Tratamiento de combinación con fármacos | |
| ES2309357T3 (es) | Nueva combinacion sinergica que comprende roflumilast y formoterol. | |
| JP2007512270A (ja) | デオキシペガニンの経口製剤およびそれらの使用 | |
| TWI897768B (zh) | 阿哌沙班膜產品用於治療血栓症之用途 | |
| CN107249595A (zh) | 灌肠剂 | |
| WO2006013914A1 (ja) | 口腔粘膜投与剤 | |
| JP2006070027A (ja) | 口腔粘膜投与剤 |